Skip to main content
. 2016 Nov 4;8(11):696. doi: 10.3390/nu8110696

Table 1.

Baseline and follow-up characteristics of 6755 study participants.

Characteristic Baseline Last Follow-up Visit
Serum 25(OH)D, nmol/L
   Mean (SD) 88.3 (42.2) 121.0 (46.2)
   Median (IQR) 81.6 (60.5–108.0) 115.0 (88.60–147.0)
Serum C-reactive protein, mg/L
   Mean (SD) 1.7 (1.8) 1.6 (1.8)
   Median (IQR) 1.0 (0.5–2.2) 0.9 (0.4–2.1)
Elevated C-reactive protein, %
   Low-risk (<1 mg/L) 47.0 51.2
   Average risk (1–2.99 mg/L) 35.6 32.6
   High risk (≥3 mg/L) 17.4 16.2
Gender (%)
   Female 52.0 52.0
   Male 48.0 48.0
Age
   Mean (SD) 50.9 (15.2) 52.4 (15.0)
Body weight status, %
   Under weight 1.0 1.0
   Normal weight 34.2 34.3
   Over weight 38.2 37.7
   Obesity 26.6 27.0
Blood pressure, % *
   Normal (<140/90 mmHg) 58.9 53.2
   Elevated (≥140/90 mmHg or anti-hypertensive medication use) 36.2 33.6
   Missing 4.9 13.2
Serum LDL-cholesterol, %
   Normal (<2.6 mmol/L) 34.3 30.0
   Elevated (≥2.6 mmol/L) 61.7 67.3
   Missing 4.0 2.7
Smoking status, %
   Never smoker 41.5 30.2
   Ex-smoker 21.6 15.6
   Current smoker 8.7 6.6
   Missing 28.2 47.6
Alcohol consumption status, %
   Non-drinker 25.3 26.6
   Drinker 42.1 41.6
   Missing 32.6 31.8
Physical activity level, %
   Low 28.3 28.3
   Moderate 21.5 21.5
   High 21.0 21.0
   Missing 29.2 29.2
Use of vitamin D-containing supplements, %
   Yes 47.4 74.2
   No 35.7 9.6
   Missing 16.9 16.2
Vitamin D dose of the supplements, Median (IQR) IU/day 3000 (2000–5000) 6000 (4000–9000)

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; LDL-cholesterol, low-density lipoprotein cholesterol; SD, standard deviation; IQR, interquartile range; * Blood pressure status was defined based on blood pressure ≥140/90 mm Hg, or a self-report of taking antihypertensive medications as elevated; Elevated LDL-cholesterol was defined as LDL-cholesterol concentration ≥2.6 mmol/L.